

Hygroline derivatives from *Schizanthus tricolor* and their anti-trypanosomatid and antiplasmodial activities

Sylvian Cretton^{a,b,*}, Grégory Genta-Jouve^c, Marcel Kaiser^{d,e}, Pascal Mäser^{d,e}, Orlando Muñoz^f, Thomas Bürgi^g, Muriel Cuendet^{a,b}, Philippe Christen^{a,b}

^a School of Pharmaceutical Sciences, University of Geneva, 1211, Geneva, 4, Switzerland

^b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211, Geneva, 4, Switzerland

^c Laboratoire Ecologie, Evolution, Interactions des Systèmes Amazoniens (LEEISA), USR 3456, Université De Guyane, CNRS Guyane, 97300, Cayenne, French Guyana, France

^d Swiss Tropical and Public Health Institute, 4002, Basel, Switzerland

^e University of Basel, 4003, Basel, Switzerland

^f Departamento de Química, Facultad de Ciencias, Universidad de Chile, Casilla 653, Santiago, Chile

^g Department of Physical Chemistry, University of Geneva, 1211, Geneva, 4, Switzerland

ARTICLE INFO

Keywords:

Schizanthus tricolor
Solanaceae
Hygroline derivatives
Pyrrolidine alkaloids
Antiparasitic activity

ABSTRACT

Chemical investigation of the alkaloid extract of the aerial parts of *Schizanthus tricolor* led to the targeted isolation of 26 hygroline derivatives of which 20 were fully characterized. They have not yet been described in the literature and their structures were established by 1D and 2D NMR, UV and IR spectroscopy, and HRESIMS. The configuration was determined by Gauge-Independent Atomic Orbital NMR chemical shift calculations supported by the advanced statistical method DP4 plus, vibrational circular dichroism, and measurement of optical rotation. Their anti-trypanosomatid, antiplasmodial and cytotoxic activities were measured. Several compounds exhibited low micromolar activity against *Plasmodium falciparum*. None of the identified molecules was cytotoxic.

1. Introduction

The genus *Schizanthus* Ruiz & Pav. from the Solanaceae family comprises 12 species and are commonly known as little bird or little butterfly. This genus is primarily native to Chile and the species grow in a large diversity of habitats, from the desert to the coast, as well as from the high Andes to areas cleared of forest in the southern region (Pérez et al., 2006). The genus is characterized by numerous tropane alkaloids. Most of them are ester derivatives from angelic, senecioic, tiglic, itaconic, mesaconic, citraconic or cinnamic acid, which generates numerous positional and configurational isomers. To date over 50 alkaloids have been isolated and characterized from this genus. However, among them only seven pyrrolidine derivatives were described, namely hygryne, hygrolines, cuscohygrines, 4-hydroxyphenylpropanoylhygryne, and 1-methyl-2-(1-methyl-2-pyrrolidinyl)-ethyl-6-deoxy-3-O-angeloyl- α -galactopyranoside (Christen et al., 2020). Pyrrolidine derivatives are a source of pharmacologically active lead compounds (Islam and Mubarak, 2020) and the object of recent synthesis due to

“their intriguing biological activities, hallucinogenic characteristics and their utility as pharmacological probes” (Bhat and Tilve, 2011). Therefore, the aim of this study was to investigate the diversity of pyrrolidine derivatives in the species *Schizanthus tricolor* Grau & Gronbach (Solanaceae) which is known to be particularly rich in alkaloids. In addition, as part of our ongoing research of undescribed antiprotozoal molecules (Cretton et al., 2010, 2014a, 2014b, 2020), the antiparasitic activity of the isolated hygroline derivatives was evaluated against *Trypanosoma brucei rhodesiense* (*T. b. rhodesiense*), *Trypanosoma cruzi* (*T. cruzi*), *Leishmania donovani* (*L. donovani*), and *Plasmodium falciparum* (*P. falciparum*).

2. Results and discussion

The alkaloid extract from the aerial parts of *S. tricolor* was analyzed by LC-HRMS/MS in positive mode. The MS/MS fragment at m/z 144.1390, characteristic of the hygroline moiety was used as a marker to identify putative pyrrolidine alkaloids (see supporting information). An early eluting broad peak displaying ion at m/z 290 $[M + H]^+$, followed

* Corresponding author. School of Pharmaceutical Sciences, University of Geneva, 1211, Geneva, 4, Switzerland.

E-mail address: sylvian.cretton@unige.ch (S. Cretton).

<https://doi.org/10.1016/j.phytochem.2021.112957>

Received 22 July 2021; Received in revised form 13 September 2021; Accepted 15 September 2021

Available online 23 September 2021

0031-9422/© 2021 The Author(s).

Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. LC-HRMS chromatogram of the alkaloid fraction of *S. tricolor* (for sake of clarity m/z values are shown without decimal).

by 17 peaks at m/z 372 $[M + H]^+$, 6 peaks at m/z 600 $[M + H]^+$, 4 peaks at m/z 420 $[M + H]^+$, and 18 peaks at m/z 454 $[M + H]^+$ were identified as putative pyrrolidine derivatives (Fig. 1). To isolate the targeted hygroline derivatives, the alkaloid extract was fractionated using flash chromatography. Further purification of the fractions was carried out by semi-preparative HPLC and afforded 20 fully characterized undescribed compounds, 1–20 (Fig. 2).

Compound 1 was obtained as a pale yellow oil, and its molecular formula $C_{14}H_{26}NO_5$ was established by HRESIMS data (m/z 290.1979 $[M + H]^+$, calcd for $C_{14}H_{27}NO_5$, 290.1962). The IR spectrum showed absorption bands attributable to hydroxy (3255 cm^{-1}) and amine (1591 cm^{-1}) groups. Analysis of NMR data (Table 1), and comparison with the literature (Muñoz et al., 1994) indicated the presence of a deoxy hexose sugar unit with proton signals at δ_H 4.72, 3.49, 3.44, 3.47, 3.86, 1.06 (H-1 to H-6, respectively) and their corresponding carbon signals at δ_C 100.1, 68.0, 70.1, 71.5, 66.4 and 16.5. The configuration of the sugar unit was determined by VCD. A positive sign of the intense glycoside band around 1160 cm^{-1} was observed on the VCD spectrum of 1 (Fig. 3) and indicates an axial glycosidic linkage in C-1, with the 1C_4 conformation (Taniguchi and Monde, 2007a,b). Therefore, the proton H-1 is oriented in equatorial position and the small coupling constant between H-1 and H-2 ($J = 3.6\text{ Hz}$) indicated that H-2 is in axial position (Fig. 4). Likewise, the coupling constants between H-2 and H-3 ($J = 10.0\text{ Hz}$) imposed an axial orientation for H-3, and an equatorial orientation for H-4 ($J = 3.4\text{ Hz}$). Due to an overlapping of the signals of H-2 to H-4 in $DMSO-d_6$, a second measurement was performed in CD_3OD , which made it possible to confirm the spin system (see supporting information, Table S3). From these data, a β -6-deoxy-L-galactose (also named β -L-fucose) unit was identified. A hygroline moiety was deduced from eight carbon signals corresponding to two methine C-2' and C-7' (δ_C 64.3 and 73.5, respectively) each linked to a heteroatom (N and O, respectively), four methylenes C-3' to C-6' (δ_C 28.4, 21.1, 55.8 and 36.7, respectively), and two methyl groups C-8' and C-9' (δ_C 21.8 and 39.2, respectively). A key HMBC correlation between H-7' at δ_H 3.78 (m, 1H) and C-1, as well as a ROE interaction between H-7' and H-1 allowed to connect the hygroline moiety to the anomeric carbon (C-1) of the fucose unit (Fig. 4). Unfortunately, the high flexibility of this molecule impeded the determination of the absolute configuration by comparison of the calculated and experimental VCD spectra. Therefore, the relative configurations at C-2' and C-7' were assigned by calculation of the Smith and Goodman DP4 probability (Smith and Goodman, 2010). Comparison of the experimental and theoretical chemical shifts indicated a $2'S^*/7'S^*$ configuration with 85.9% probability (see supporting

information). To confirm this result, the absolute configuration of the hygroline moiety was determined by an acidic hydrolysis of 1 followed by the optical rotation measurement of the hygroline moiety $[\alpha]_D^{22} - 48.2$ (c 0.05, EtOH). A comparison with the literature $[\alpha]_D^{24} - 46.9$ (c 1.00, EtOH) (Liniger et al., 2013) corroborated the $2'S^*/7'S^*$ configuration. Likewise, the optical rotation of the resulting sugar was compared to that of L-fucose and confirmed the identity of the 6-deoxy hexose. Compound 1 was thus identified as 1(*S*)-methyl-2-(1-methyl-2(*S*)-pyrrolidinyl)ethyl 6-deoxy- β -galactopyranoside, and named schizanthoside A1.

Compound 2 shares the same HRESIMS protonated molecule $[M + H]^+$ at m/z 290.1979 (calcd for $C_{14}H_{27}NO_5$, 290.1962) than 1, and consequently both compounds are isomers. IR and NMR data are also very similar. To distinguish them, a DP4 calculation was carried out and established a $2'R^*/7'S^*$ configuration at 81.1% for 2. An acid hydrolysis of 2 followed by the measurement of the optical rotation of the hygroline moiety $[\alpha]_D^{22} + 98.2$ (c 0.05, EtOH), and comparison with the literature (Liniger et al., 2013) confirmed the presence of a (+)-pseudohygroline moiety for 2. L-fucose was also confirmed by comparison of its optical rotation with a standard sample. Compound 2 was thus identified as 1(*S*)-methyl-2-(1-methyl-2(*R*)-pyrrolidinyl)ethyl 6-deoxy- β -galactopyranoside, and named schizanthoside A2.

The HRMS, IR and NMR data of compound 3 are very similar to those of 1 and 2. Nevertheless, a noticeable difference lies in the multiplicity and the constant coupling of H-4 at δ_H 2.77 (t, $J = 9.2\text{ Hz}$, 1H), indicating that H-4 is axially oriented and characteristic of a 6-deoxy-glucose ring (Fig. 4). According to the DP4 probability, a $2'R^*/7'S^*$ configuration was established (82.8%). Therefore, compound 3 was identified as 1(*S*)-methyl-2-(1-methyl-2(*R*)-pyrrolidinyl)ethyl 6-deoxy- β -glucopyranoside, and named schizanthoside A3.

The molecular formula $C_{19}H_{33}O_6$ of 4 was established by HRESIMS from the protonated molecule $[M + H]^+$ at m/z 372.2385 (calcd for $C_{19}H_{34}NO_6$, 372.2381). MS/MS fragment at m/z 83.0499 (see supporting information) suggested the presence of a monocarboxylic isomeric C_5 acid, namely angelic, senecioic or tiglic acids that are known to be present in the genus *Schizanthus* (Christen et al., 2020). Analysis of 1H -NMR data revealed signals of two methyl groups at δ_H 1.97 (dq, $J = 7.3$ and 1.6 Hz , H-4'') and at δ_H 1.86 (t, $J = 1.6\text{ Hz}$, H-5''), and a vinylic proton at δ_H 6.18 (qd, $J = 7.3$ and 1.6 Hz , H-3''). On the DEPTQ spectrum, a carbonyl signal at δ_C 167.1 (C-1''), two sp^2 carbon signals at δ_C 127.3 (C-2'') and 138.7 (C-3''), and two methyl signals at δ_C 15.8 (C-4'') and 20.5 (C-5'') were observed. 2D experiments (COSY and HMBC)




Fig. 2. Chemical structures of compounds 1–20.

allowed to interconnect the different elements, and to identify angelic acid as esterifying acid (De la Fuente et al., 1988). A deshielding of proton H-2 in the fucose ring located the esterification of angelic acid in C-2 (Muñoz et al., 1994). According to the DP4 probability, a 2'R*/7'S* configuration was established (93.2%) and the compound was characterized as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-2-O-angeloyl-β-galactopyranoside and named schizanthoside B1.

Compound 5 differs from compound 4 by the nature of the C₅ acid esterifying the fucose skeleton in C-2. Indeed, in the ¹H-NMR spectrum a signal corresponding to the vinylic proton H-2'' at δ_H 5.82 (d, J = 2.0 Hz) was observed. The COSY experiment demonstrated that H-2'' correlated with two methyl groups at δ_H 1.96 (d, J = 2.0 Hz, H-4''), and at δ_H 2.21 (d, J = 2.0 Hz, H-5''). This coupling system and the chemical shifts are characteristic of senecioidic acid (De la Fuente et al., 1988). According to the DP4 probability, a 2'S*/7'S* configuration was established (79.4%), and 5 was characterized as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl)ethyl 6-deoxy-2-O-senecioidyl-β-galactopyranoside, and named schizanthoside B2.

A comparison of the NMR data of 6 with the literature (Muñoz et al.,


1994) indicated that 6 was characterized by the following structure 1-methyl-2-(1-methyl-2-pyrrolidinyl)ethyl 6-deoxy-3-O-angeloyl-galactopyranoside. DP4 calculation allowed to attribute a 2'S*/7'S* configuration and the alkaloid was identified as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl)ethyl 6-deoxy-3-O-angeloyl-β-galactopyranoside, and named schizanthoside B3. Compound 6 has an optical rotation value of [α]_D²² - 71.6 (c 0.05, MeOH), which differs from the published data [α]_D²⁰ + 14.2 (c 1.03, EtOH) indicating a difference in the stereochemistry of the hygroline and/or the sugar moiety. Unfortunately, no data about the stereochemistry was published, and prevents a comparison of the two stereoisomers.

Compound 7 is similar to 6 except that senecioidic acid, characterized by H-2'' at δ_H 5.72 and two methyl groups at δ_H 1.88 (H-4''), and at δ_H 2.10 (H-5''), is esterified in C-3 instead of angelic acid for 6. DP4 calculation allowed to attribute at 80.5% a 2'S*/7'S* configuration and 7 was identified as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl)ethyl 6-deoxy-3-O-senecioidyl-β-galactopyranoside, and named schizanthoside B4.

Compound 8 is composed of a fucose unit esterified by angelic acid with the characteristic vinylic proton at δ_H 6.10 (qd, J = 7.2 and 1.7 Hz,

Table 1¹H and ¹³C NMR data of compounds 1–3 (600 and 150 MHz, in DMSO-*d*₆, δ in ppm).

Position	1 δ_{H} (J in Hz)	δ_{C} , type	2 δ_{H} (J in Hz)	δ_{C} , type	3 δ_{H} (J in Hz)	δ_{C} , type
1	4.72, d (3.6)	100.1, CH	4.65, d (2.8)	100.2, CH	4.64, d (3.9)	99.9, CH
2	3.49, dd (10.0, 3.6)	68.0, CH	3.51, m	68.3, CH	3.17, dd (9.7, 3.9)	72.3, CH
3	3.44, d (10.0, 3.4)	70.1, CH	3.51, m	69.6, CH	3.33, t (9.2)	72.9, CH
4	3.47, d (3.4)	71.5, CH	3.47, brs	71.7, CH	2.77, t (9.2)	75.8, CH
5	3.86, q (6.5)	66.4, CH	3.85, qd (6.6, 1.4)	66.1, CH	3.55, m	67.5, CH
6	1.06, d (6.5)	16.5, CH ₃	1.06, d (6.6)	16.5, CH ₃	1.09, d (6.3)	17.8, CH ₃
2'	2.52, m	64.3, CH	2.42, m	62.5, CH	2.59, m	62.7, CH
3'	1.93, m	28.4, CH ₂	1.95, m	30.2, CH ₂	2.00, m	29.9, CH ₂
4'	1.62, m	21.1, CH ₂	1.42, m	21.4, CH ₂	1.46, m	21.3, CH ₂
5'	3.09, brs 2.33, brs	55.8, CH ₂	2.96, ddd (9.5, 7.4, 3.4)	56.4, CH ₂	3.04, m 2.26, d (9.2)	56.0, CH ₂
6'	1.73, m 1.62, m	36.7, CH ₂	1.83, ddd (13.2, 9.0, 3.9) 1.22, m	40.6, CH ₂	1.86, ddd (13.4, 9.4, 3.9) 1.30, td (9.4, 4.6) 3.63, m	40.0, CH ₂
7'	3.78, m	73.5, CH	3.61, ddd (9.4, 6.2, 3.4)	74.1, CH		74.5, CH
8'	1.17, d (6.0)	21.8, CH ₃	1.17, d (6.2)	22.5, CH ₃	1.18, d (6.2)	22.5, CH ₃
9'	2.38, s	39.2, CH ₃	2.23, s	39.9, CH ₃	2.30, s	39.5, CH ₃

**Fig. 3.** Experimental VCD spectra of compounds 1, 16 and 17.

H-3''), and two methyl groups at δ_{H} 1.93 (dq, $J = 7.2$ and 1.7 Hz, H-4''), and at δ_{H} 1.86 (t, $J = 1.7$ Hz, H-5''). The esterification site was located in C-4 by the deshielding of proton H-4 at δ_{H} 5.13 (d, $J = 3.2$ Hz), and a

HMBC correlation between H-4 and C-1'' at δ_{C} 167.0. DP4 calculation allowed to attribute a 2'R*/7'S* configuration and the compound was identified as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-4-O-angeloyl- β -galactopyranoside, and named schizanthoside B5.

Compound 9 has the same structure as 8 except that DP4 calculation determined 2'S*/7'S* configuration for the hygroline moiety. Therefore, 9 was identified as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl)ethyl 6-deoxy-4-O-angeloyl- β -galactopyranoside, and named schizanthoside B6.

Compound 10 differs from 8 and 9 by the presence of senecioic acid esterified in C-4. The nature of the acid was identified by the proton H-2'' at δ_{H} 5.72 and two methyl groups at δ_{H} 1.89 (H-4''), and at δ_{H} 2.10 (H-5''). DP4 calculation allowed to determine a 2'S*/7'S* configuration and 10 was identified as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl)ethyl 6-deoxy-4-O-seneciyl- β -galactopyranoside, and named schizanthoside B7.

The molecular formula C₂₄H₃₉NO₇ of compound 11 was deduced from the protonated molecule [M + H]⁺ at m/z 454.2797 (calcd for C₂₄H₄₀NO₇, 454.2800). A comparison with the molecular formula of the isomers at m/z 372.2385 indicated a difference of C₅H₆O, which could correspond to an additional C₅ acid esterified on the fucose moiety. This assumption was corroborated by the analysis of the ¹H-NMR spectrum where two vinylic protons at δ_{H} 6.19 (1H, qd, $J = 7.3$ and 1.9 Hz, H-3'') and at δ_{H} 6.11 (1H, qd, $J = 7.2$ and 1.5 Hz, H-3'''), and four methyl groups at δ_{H} 1.87 (6H, m, H-4'') and H-4'''), and at δ_{H} 1.78 (6H, dt, $J = 8.9$ and 1.6 Hz, H-5'' and H-5''') were observed. The chemical shifts are characteristic of two angelic acids and their location on the sugar was determined in C-2 and C-3 by the deshielding of protons H-2 at δ_{H} 5.10 (1H, dd, $J = 11.0$ and 3.8 Hz), and H-3 at δ_{H} 5.19 (1H, dd, $J = 11.0$ and 3.2 Hz). In addition, HMBC correlations were observed from H-2 to C-1'' at δ_{C} 166.5 and from H-3 to C-1''' at δ_{C} 166.6. DP4 calculation determined a 2'R*/7'S* configuration for the hygroline part and 11 was characterized as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-2,3-O-diangeloyl- β -galactopyranoside, and named schizanthoside C1.

Compound 12 is an isomer of 11 and showed close structural similarities. However, according to NMR data the second angelic acid is esterified in C-4 instead of C-3 in 11. Indeed, HMBC correlations were observed between H-2 at δ_{H} 4.76 (1H, dd, $J = 10.6$ and 3.8 Hz) and C-1'' at δ_{C} 166.8, and between H-4 at δ_{H} 5.21 (1H, d, $J = 3.6$ Hz) and C-1''' at δ_{C} 166.9. DP4 calculation determined a 2'R*/7'S* configuration for the hygroline part and 12 was characterized as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-2,4-O-diangeloyl- β -galactopyranoside, and named schizanthoside C2.

The HRMS and spectral data of compound 13 were very similar to those of compound 11. Nevertheless, an analysis of the coupling constants of the sugar protons pointed out a difference in the multiplicity. The coupling constant of H-4 at δ_{H} 3.21 (1H, t, $J = 9.3$ Hz) indicated that H-4 is axially oriented. DP4 calculation determined a 2'R*/7'S* configuration for the hygroline moiety and 13 was characterized as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-2,3-O-diangeloyl- β -glucopyranoside, and named schizanthoside C3.

Compound 14 contrasts from the previous isomers (11–13) by the presence of tiglic acid revealed by the vinylic proton at δ_{H} 6.67 (1H, qd, $J = 7.2$ and 1.8 Hz, H-3'') (De la Fuente et al., 1988). HMBC correlation from H-3 at δ_{H} 5.06 (1H, dd, $J = 10.6$ and 3.5 Hz) to C-1'' at δ_{C} 166.1 allowed to locate tiglic acid in C-3. Likewise, a correlation from H-4 at δ_{H} 5.24 (1H, d, $J = 3.5$ Hz) to C-1''' at δ_{C} 166.3 positioned angelic acid in C-4. A 2'S*/7'S* configuration was determined by DP4 calculation for the hygroline moiety and 14 was characterized as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl)ethyl 6-deoxy-3-O-tigloyl-4-O-angeloyl- β -glucopyranoside, and named schizanthoside C4.

Compounds 15 and 16 share the same fucose moiety esterified in C-3 and C-4 by two angelic acids. The sites of esterification were elucidated unambiguously by the deshielding of protons H-3 at δ_{H} 5.09 (1H, dd, $J = 10.6$ and 3.5 Hz) for 15 and at δ_{H} 5.11 (1H, dd, $J = 10.5$ and 3.5 Hz) for 16, and by H-4 at δ_{H} 5.28 (1H, d, $J = 3.5$ Hz) for 15 and at δ_{H} 5.26 (1H,




Fig. 4. Key HMBC (blue arrows), ROESY (green arrows) correlations and selected coupling constants (red dashed arrow) of compounds **1** and **3**. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)




Fig. 5. Key HMBC (blue arrows), ROESY (green arrows) correlations and selected coupling constants (red dashed arrow) of compound **19**. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

dd, $J = 3.5$ and 1.3 Hz) for **16**. For both compounds, HMBC correlations from H-3 to C-1'' and H-4 to C-1''' confirmed the location of the esterified acids on the fucose moiety. However, a 2'S*/7'S* configuration for **15** and a 2'R*/7'S* for **16** were determined by DP4 calculation. Thus, **15** and **16** were described as 1(S)-methyl-2-(1-methyl-2(S)-pyrrolidinyl) ethyl 6-deoxy-3,4-O-diangeloyl- β -galactopyranoside and 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl) ethyl 6-deoxy-3,4-O-diangeloyl- β -galactopyranoside, and named schizanthosides C5 and C6, respectively.

Compound **17** exhibited an HRESIMS protonated molecule $[M + H]^+$ at m/z 420.2388 (calcd for $C_{23}H_{34}NO_6$, 420.2381), indicating a molecular formula $C_{23}H_{33}NO_6$. NMR data showed the presence of a *cis*-cinnamoyl group characterized by two olefinic methine signals at δ_H 6.06 (1H, d, $J = 12.8$ Hz, H-2'') and at δ_H 7.01 (1H, d, $J = 12.8$ Hz, H-3''), and five aromatic proton signals at δ_H 7.35 (3H, m, H-6'' to H-8'') and δ_H 7.66 (2H, dd, $J = 7.4$ and 2.2 Hz, H-5'' and H-9''). The coupling constant value $J_{2'',3''}$ of 12.8 Hz indicated a *cis* geometry of the double bond. Key HMBC correlation from proton H-4 at δ_H 5.11 (1H, d, $J = 3.6$ Hz) to C-1'' at δ_C 165.4 allowed to determine the connection of the cinnamoyl

moiety to the deoxy galactosyl unit in C-4. A 2'R*/7'S* configuration was established by DP4 calculation and the compound was identified as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-4-O-(Z)-cinnamoyl- β -galactopyranoside, and named schizanthoside D1.

Compound **18** shares the same protonated molecule $[M + H]^+$ at m/z 420.2388 (calcd for $C_{23}H_{34}NO_6$, 420.2381) as **17**. As for the latter, a cinnamoyl group was characterized by two olefinic methine signals at δ_H 6.66 (1H, d, $J = 16.0$ Hz, H-2'') and δ_H 7.65 (1H, d, $J = 16.0$ Hz, H-3''), and five aromatic proton signals at δ_H 7.43 (3H, m, H-6'' to H-8'') and δ_H 7.74 (2H, m, H-5'' and H-9''). Unlike **17**, the coupling constant value $J_{2'',3''}$ of 16.0 Hz implied a *trans* geometry of the double bond. As for **17**, a key HMBC correlation from proton H-4 at δ_H 5.16 (1H, d, $J = 3.7$ Hz) to C-1'' at δ_C 165.8 allowed to determine the connection of the cinnamoyl moiety to the 6-deoxygalactopyranosyl ring in C-4. A 2'R*/7'S* configuration was established by DP4 calculation and the compound was characterized as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-4-O-(E)-cinnamoyl- β -galactopyranoside, and named schizanthoside D2.

The molecular formula of the alkaloid **19** is $C_{30}H_{49}NO_{11}$, and was deduced from the protonated molecule $[M + H]^+$ at m/z 600.3386 (calcd for $C_{30}H_{50}NO_{11}$, 600.3379). The analysis of the NMR data showed the presence of a β -L-fucose unit esterified with a hygroline moiety in C-1, two tiglic acids in C-2 and C-3, and a rhamnose unit in C-4. The structure of the second sugar unit was inferred from the coupling constant system (1.7 Hz for the anomeric proton, 3.2 Hz between H-2'''' and H-3''', 9.4 Hz between H-3''', H-4'''' and H-5'''), as well as a ROESY correlation between H-3'''' and H-5'''' (Fig. 5). A 2'R*/7'S* configuration was determined by DP4 calculation and the compound was identified as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-2,3-O-ditigloyl-4-rhamnosyl- β -galactopyranoside, and named schizanthoside E1.


Compound **20** is similar to **19** except that two angelic acids are esterified in C-2 and C-3 in the fucose unit instead of two tiglic acids in **19**. A 2'R*/7'S* configuration was determined by DP4 calculation and the compound was identified as 1(S)-methyl-2-(1-methyl-2(R)-pyrrolidinyl)ethyl 6-deoxy-2,3-O-diangeloyl-4-rhamnosyl- β -galactopyranoside, and named schizanthoside E2.

Six additional isomers at m/z 372 were isolated but not fully characterized due to the low amount of the compounds. Indeed, the NMR spectra did not allow to observe all the carbons and protons of the hygroline moiety (see supporting information, Tables 1 and 2), and consequently to determine the stereochemistry. Nevertheless, the nature of the sugar, the C₅ acids and their location on the 6-deoxy-hexose were elucidated without ambiguity. Their structures are depicted in Fig. 6.

The alkaloid extract and seventeen isolated compounds were tested for their *in vitro* growth inhibition of *T. b. rhodesiense*, *T. cruzi*,

Table 2¹H NMR data of compounds 4–10 (600 MHz, in DMSO-*d*₆ or * CD₃OD, δ in ppm, *J* in Hz).

Position	4	5*	6	7	8	9	10
1	4.90, d (3.9)	5.08, d (3.7)	4.73, d (3.9)	4.76, d (3.9)	4.79, d (4.0)	4.93, d (3.8)	4.77, d (3.8)
2	4.76, dd (10.6, 3.9)	4.91, dd (10.5, 3.8)	3.84, dd (10.7, 3.9)	3.70, dd (10.9, 3.2)	3.55, dd (10.3, 3.7)	3.56, dd (10.0, 4.0)	3.44, m
3	3.81, dd (10.5, 3.3)	3.92, dd (10.5, 3.4)	4.83, dd (10.7, 3.2)	4.80, dd (10.9, 3.2)	3.77, dd (10.3, 3.7)	3.70, dd (10.0, 3.3)	3.67, dd (10.1, 3.6)
4	3.56, d (3.4)	3.73, d (3.2)	3.69, d (3.2)	3.60, s	5.13, d (3.2)	5.14, d (3.3)	5.04, d (3.6)
5	3.92, q (6.5)	4.07, q (6.6)	3.94, q (6.5)	3.94, q (6.6)	4.10, q (6.5)	4.12, q (6.6)	4.06, q (6.7)
6	1.09, d (6.5)	1.22, d (6.6)	1.07, d (6.5)	1.06, d (6.6)	0.95, d (6.5)	0.96, d (6.5)	0.92, d (6.5)
2'	2.10, m	3.29	2.33, m	2.18, m	3.10, m	3.15, m	2.19, m
3'	1.69, m	2.20, m	1.93, m	1.82, m	2.15, m	1.94, m	1.87, m
	1.30, m	1.73, m	1.41, m	1.54, m	1.59, m	1.81, m	1.51, m
4'	1.58, m	2.00, m	1.60, m	1.61, m	1.81, m	1.90, m	1.63, m
	1.48, m					1.81, m	
5'	2.91, m	3.61, brs	2.92, m	2.87, m	3.28, m 2.67, m	3.34, m	2.95, m
	1.95, m	2.99, brs	2.07, q (8.9)	2.06, m		2.80, m	2.09, m
6'	1.81, m	2.13, m	1.88, m	1.73, m	1.92, m	1.93, m	1.68, m
	1.08, m	1.59, t (12.2)	1.23, m	1.56, m	1.49, m	1.82, m	1.59, m
7'	3.52, m	3.70, m	3.66, m	3.78, m	3.68, m	3.96, m	3.74, m
8'	1.17, d (6.1)	1.34, d (6.2)	1.20, d (6.3)	1.18, d (6.1)	1.21, d (6.2)	1.22, d (6.1)	1.16, d (6.2)
9'	2.15, s	2.86, s	2.20, s	2.22, s	2.52, s	2.68, s	2.24, s
2''		5.82, d (2.0)		5.72, s			5.72, s
3''	6.18, qd (7.3, 1.6)		6.08, qd (7.3, 1.6)		6.10, qd (7.2, 1.7)	6.12, qd (7.2, 1.7)	
4''	1.97, dq (7.3, 1.6)	1.96, d (2.0)	1.94, dq (7.3, 1.6)	1.88, s	1.93, dq (7.2, 1.7)	1.94, dq (7.2, 1.7)	1.89, s
5''	1.86, t (1.6)	2.21, d (2.0)	1.86, t (1.6)	2.10, s	1.86, t (1.7)	1.84, t (1.7)	2.10, s

**Fig. 6.** Chemical structures of compounds 21–26.

L. donovani and *P. falciparum*, which are the etiological agents of sleeping sickness, Chagas disease, visceral leishmaniasis and tropical malaria, respectively. The cytotoxicity in uninfected rat skeletal L6 cells was also evaluated. The data obtained are summarized in Table 7. A significant inhibitor ($IC_{50} < 10 \mu\text{g/mL}$) of the alkaloid extract was observed only towards *P. falciparum*. Among the isolated compounds, compounds 11–16 and 18 inhibited the etiologic agent of malaria with $IC_{50} < 10 \mu\text{M}$. Thus the presence of two C₅ acids esterifying the sugar unit appears to be essential for the antiplasmodial activity because compounds with one C₅ acid only (compounds 4, 6–10) or without C₅ acid (compounds 1–3) were inactive against the parasite (Table 7). The nature of the C₅ acid (angelic, senecioic or tiglic acid), their location on the sugar unit as well as the stereochemistry of the hygroline seemed to have a low influence on the antiplasmodial activity. In addition, the *trans*-cinnamoyl moiety esterified in C-4 for 18 was beneficial for the

antiplasmodial activity ($IC_{50} = 6.3 \mu\text{M}$), whereas the *cis*-cinnamoyl moiety for 17 was detrimental ($IC_{50} = 26.1 \mu\text{M}$). No cytotoxicity was detected for all compounds.

3. Conclusions

The targeted investigation of pyrrolidine derivatives in the aerial parts of *S. tricolor* resulted in the isolation and characterization of 20 undescribed alkaloids named schizanthosides A1–A3 (1–3), B1–B7 (4–10), C1–C6 (11–16), D1–D2 (17–18), and E1–E2 (19–20). Six other pyrrolidine alkaloids were also isolated but not fully characterized due to lack of material. Compounds 11–16 and 18 showed a significant inhibitory activity towards *P. falciparum* with an $IC_{50} < 10 \mu\text{M}$.

Table 3¹³C NMR data of compounds 4–10 (150 MHz, in DMSO-d₆ or * CD₃OD, δ in ppm, C type).

Position	4	5*	6	7	8	9	10
1	97.2, CH	99.4, CH	100.0, CH	100.0, CH	100.6, CH	100.1, CH	99.9, CH
2	71.4, CH	72.4, CH	65.3, CH	65.4, CH	68.8, CH	68.3, CH	68.6, CH
3	66.9, CH	69.1, CH	73.5, CH	73.0, CH	67.4, CH	67.6, CH	68.0, CH
4	71.8, CH	73.7, CH	68.9, CH	69.2, CH	73.9, CH	73.8, CH	73.0, CH
5	66.0, CH	67.9, CH	65.8, CH	66.2, CH	64.8, CH	65.2, CH	64.9, CH
6	16.3, CH ₃	16.4, CH ₃	16.3, CH ₃	16.3, CH ₃	16.2, CH ₃	16.3, CH ₃	16.2, CH ₃
2'	61.9, CH	67.4, CH	62.2, CH	63.8, CH	64.0, CH	65.5, CH	63.7, CH
3'	30.1, CH ₂	30.3, CH ₂	30.4, CH ₂	28.7, CH ₂	28.9, CH ₂	27.3, CH ₂	29.1, CH ₂
4'	21.4, CH ₂	22.2, CH ₂	21.5, CH ₂	21.2, CH ₂	20.8, CH ₂	20.7, CH ₂	21.3, CH ₂
5'	56.6, CH ₂	57.1, CH ₂	56.5, CH ₂	56.2, CH ₂	55.3, CH ₂	55.2, CH ₂	56.2, CH ₂
6'	41.3, CH ₂	39.0, CH ₂	40.7, CH ₂	37.5, CH ₂	38.2, CH ₂	34.6, CH ₂	38.0, CH ₂
7'	74.8, CH	75.9, CH	74.1, CH	73.7, CH	75.0, CH	74.1, CH	73.8, CH
8'	22.6, CH ₃	22.5, CH ₃	22.5, CH ₃	21.9, CH ₃	22.2, CH ₃	21.7, CH ₃	21.9, CH ₃
9'	39.9, CH ₃	39.4, CH ₃	40.0, CH ₃	39.6, CH ₃	38.5, CH ₃	38.1, CH ₃	39.8, CH ₃
1''	167.1, C	167.6, C	167.3, C	165.6, C	167.0, C	167.0, C	165.6, C
2''	127.3, C	116.5, CH	128.0, C	116.3, CH	127.8, C	127.7, C	116.0, CH
3''	138.7, CH	160.5, C	136.8, CH	155.9, C	136.8, CH	137.1, CH	156.3, C
4''	15.8, CH ₃	27.5, CH ₃	15.5, CH ₃	26.8, CH ₃	15.5, CH ₃	15.6, CH ₃	26.9, CH ₃
5''	20.4, CH ₃	20.5, CH ₃	20.3, CH ₃	19.9, CH ₃	20.4, CH ₃	20.5, CH ₃	20.0, CH ₃

Table 4¹H NMR data of compounds 11–16 (600 MHz, in DMSO-d₆, δ in ppm, *J* in Hz).

Position	11	12	13	14	15	16
1	5.01, d (3.8)	5.00, d (3.9)	5.03, d (3.9)	4.85, d (3.9)	4.86, d (3.8)	4.91, d (3.9)
2	5.10, dd (11.0, 3.8)	4.76, dd (10.6, 3.8)	4.64, dd (10.5, 3.8)	3.79, dd (10.6, 3.8)	3.80, dd (10.6, 3.8)	3.70, dd (10.5, 3.8)
3	5.19, dd (11.0, 3.2)	4.09, dd (10.6, 3.6)	5.31, dd (10.5, 9.3)	5.06, dd (10.6, 3.5)	5.09, dd (10.6, 3.5)	5.11, dd (10.5, 3.5)
4	3.80, d (3.6)	5.21, d (3.6)	3.21, t (9.3)	5.24, d (3.5)	5.28, d (3.5)	5.26, dd (3.5, 1.3)
5	4.04, dd (6.5, 1.3)	4.17, q (6.5)	3.78, m	4.21, dd (6.4, 1.3)	4.21, m	4.23, dd (6.4, 1.3)
6	1.12, d (6.5)	0.98, d (6.5)	1.18, d (6.3)	1.00, d (6.6)	1.00, d (6.8)	1.11, d (6.5)
2'	2.06, m	2.08, m	2.06, m	2.33, m	2.33, d (9.9)	2.15, m
3'	1.68, m	1.69, m	1.66, m	1.95, m	1.95, m	1.83, m
4'	1.30, m	1.29, m	1.29, m	1.40, m	1.42, m	1.54, m
5'	1.57, m	1.57, m	1.57, m	1.59, m	1.60, m	1.62, m
6'	1.48, m	1.48, m	1.46, m			
5''	2.87, m	2.89, m	2.86, m	2.91 m	2.91 m	2.85, m
	1.90, m	1.93, m	1.88, m	2.06 m	2.09 m	2.01, d (9.0)
6''	1.85, m	1.84, m	1.87, m	1.89, m	1.90, m	1.76, m
7''	1.09, m	1.09, m	1.10, m	1.25, m	1.25, m	1.58, m
8''	3.59, m	3.57, m	3.62, m	3.71, m	3.73, m	3.82, m
8'	1.22, d (6.1)	1.19, d (6.1)	1.23, d (6.2)	1.22, d (6.2)	1.23, d (6.1)	1.21, d (6.5)
9'	2.13, s	2.14, s	2.13, s	2.19, s	2.20, s	2.22, s
3'''	6.19, qd (7.3, 1.9)	6.20, qd (7.3, 1.7)	6.21, qd (7.3, 1.7)	6.67, qd (7.2, 1.8)	6.08, q (7.2, 1.6)	6.07, qd (7.2, 1.6)
4'''	1.87, m	1.96, m	1.89, m	1.73, dd (7.0, 1.4)	1.87, m	1.86, m
5'''	1.78, dt (8.9, 1.6)	1.87, dt (8.9, 1.6)	1.75, t (1.6)	1.70, t (1.4)	1.74, m	1.74, m
3''''	6.11, qd (7.2, 1.5)	6.14, qd (7.2, 1.5)	6.05, qd (7.2, 1.6)	6.16, qd (7.2, 1.6)	6.17, q (7.4, 1.7)	6.17, qd (7.1, 1.7)
4''''	1.87, m	1.96, m	1.84, m	1.90, m	1.92, dd (7.4, 1.7)	1.92, d (7.3)
5''''	1.78, dt (8.9, 1.6)	1.87, dt (8.9, 1.6)	1.79, t (1.6)	1.86, t (1.6)	1.87, m	1.86, m

Table 5¹³C NMR data of compounds 11–16 (150 MHz, in DMSO-d₆, δ in ppm, C type).

Position	11	12	13	14	15	16
1	97.1, CH	97.2, CH	96.3, CH	99.5, CH	99.7, CH	100.2, CH
2	68.3, CH	71.4, CH	71.4, CH	65.9, CH	66.2, CH	66.8, CH
3	70.1, CH	64.7, CH	71.2, CH	70.3, CH	70.3, CH	71.2, CH
4	68.9, CH	74.0, CH	72.9, CH	70.6, CH	71.0, CH	71.5, CH
5	65.9, CH	64.5, CH	67.3, CH	63.8, CH	64.1, CH	64.9, CH
6	16.1, CH ₃	16.1, CH ₃	17.0, CH ₃	15.6, CH ₃	15.9, CH ₃	16.4, CH ₃
2'	61.8, CH	61.8, CH	61.5, CH	61.9, CH	62.2, CH	64.1, CH
3'	30.1, CH ₂	30.1, CH ₂	29.9, CH ₂	30.1, CH ₂	30.4, CH ₂	29.2, CH ₂
4'	21.4, CH ₂	21.3, CH ₂	21.1, CH ₂	21.2, CH ₂	21.5, CH ₂	21.7, CH ₂
5'	56.7, CH ₂	56.6, CH ₂	56.4, CH ₂	56.2, CH ₂	56.5, CH ₂	56.7, CH ₂
6'	41.4, CH ₂	41.3, CH ₂	41.3, CH ₂	40.6, CH ₂	40.7, CH ₂	38.1, CH ₂
7'	75.3, CH	75.3, CH	75.4, CH	74.4, CH	74.6, CH	74.6, CH
8'	22.7, CH ₃	22.6, CH ₃	22.5, CH ₃	22.1, CH ₃	22.4, CH ₃	22.3, CH ₃
9'	39.9, CH ₃	39.9, CH ₃	39.7, CH ₃	39.9, CH ₃	40.0, CH ₃	40.2, CH ₃
1''	166.5, C	166.8, C	165.9, C	166.1, C	166.5, C	167.0, C
2''	127.3, C	127.1, C	126.2, C	127.6, C	127.3, C	127.8, C
3''	139.5, CH	139.3, CH	139.9, CH	136.9, CH	137.8, CH	137.9, CH
4''	15.4, CH ₃	15.6, CH ₃	15.4, CH ₃	13.9, CH ₃	15.4, CH ₃	15.8, CH ₃
5''	20.1, CH ₃	20.4, CH ₃	19.8, CH ₃	11.4, CH ₃	19.9, CH ₃	20.4, CH ₃
1'''	166.6, C	166.9, C	166.3, C	166.3, C	166.6, C	167.1, C
2'''	126.7, C	127.6, C	127.2, C	126.8, C	127.0, C	127.5, C
3'''	137.8, CH	137.3, CH	136.4, CH	137.5, CH	138.2, CH	138.6, CH
4'''	15.6, CH ₃	15.7, CH ₃	15.1, CH ₃	15.1, CH ₃	15.5, CH ₃	16.0, CH ₃
5'''	20.2, CH ₃	20.4, CH ₃	20.0, CH ₃	20.0, CH ₃	20.3, CH ₃	20.7, CH ₃

4. Experimental

4.1. General experimental procedures

Optical rotations were measured on a JASCO P-1030 (Easton, MD, USA) polarimeter. VCD spectra were recorded on a Bruker PMA 50 accessory coupled to a Tensor 27 Fourier transform infrared spectrometer (Billerica, MA, USA). A photoelastic modulator (Hinds PEM 90,

Table 6
¹H and ¹³C NMR data of compounds 17–20 (600 and 150 MHz, in DMSO-d₆, δ in ppm).

Position	17 δ _H (J in Hz)	δ _C , type	18 δ _H (J in Hz)	δ _C , type	19 δ _H (J in Hz)	δ _C , type	20 δ _H (J in Hz)	δ _C , type
1	4.72, d (3.9)	100.0, CH	4.78, d (3.8)	100.0, CH	5.04, d (3.8)	96.8, CH	5.06, d (3.9)	96.9, CH
2	3.48, dd (10.2, 3.9)	68.2, CH	3.64, dd (10.3, 3.8)	68.4, CH	4.98, dd (11.1, 3.8)	68.2, CH	5.00, dd (11.2, 3.9)	68.1, CH
3	3.76, dd (10.2, 3.6)	67.1, CH	3.78, dd (10.3, 3.7)	67.1, CH	5.19, dd (11.1, 3.2)	68.9, CH	5.27, dd (11.2, 3.2)	68.8, CH
4	5.11, d (3.6)	74.0, CH	5.16, d (3.7)	74.0, CH	4.01, d (3.2)	76.5, CH	4.03, d (3.2)	76.3, CH
5	4.08, q (6.6)	64.4, CH	4.11, q (6.6)	64.5, CH	4.06, q (6.6)	65.9, CH	4.08, q (6.6)	66.1, CH
6	0.96, d (6.6)	16.0, CH ₃	0.97, d (6.6)	16.0, CH ₃	1.14, d (6.6)	16.0, CH ₃	1.15, d (6.6)	16.2, CH ₃
2'	2.34, m	62.0, CH		62.1, CH	2.09, m	62.0, CH	2.01, m	61.8, CH
3'	1.95, m	30.0, CH ₂	1.99, m	29.9, CH ₂	1.66, m	29.7, CH ₂	1.66, m	30.1, CH ₂
	1.40, m		1.44, m		1.30, m		1.28, m	
4'	1.61, m	21.2, CH ₂	1.65, m	21.2, CH ₂	1.57, m	21.1, CH ₂	1.55, m	21.4, CH ₂
					1.45, m		1.46, m	
5'	2.92, m	56.2, CH ₂	2.98, m	56.1, CH ₂	2.92, m	56.2, CH ₂	2.86, m	56.7, CH ₂
	2.06, m		2.16, m		1.92, m		1.87, m	
6'	1.84, m	40.6, CH ₂	1.87, m	40.3, CH ₂	1.87, m	40.8, CH ₂	1.85, m	41.5, CH ₂
	1.20, m		1.26, m		1.13, m		1.07, ddd (12.8, 10.0, 2.6)	
7'	3.63, m	74.3, CH	3.65, m	74.3, CH	3.59, ddd (9.2, 6.2, 2.7)	75.2, CH	3.59, m	75.5, CH
8'	1.18, d (6.2)	22.3, CH ₃	1.20, d (6.3)	22.1, CH ₃	1.21, d (6.2)	22.3, CH ₃	1.21, d (6.1)	22.6, CH ₃
9'	2.19, s	39.7, CH ₃	2.25, s	39.6, CH ₃	2.15, s	39.6, CH ₃	2.11, s	39.8, CH ₃
1''		165.4, C		165.8, C		166.5, C		166.2, C
2''	6.06, d (12.8)	119.4, CH	6.66, d (16.0)	118.1, CH		127.6, C		126.3, C
3''	7.01, d (12.8)	141.9, CH	7.65, d (16.0)	144.2, CH	6.73, m	138.0, CH	6.25, qd (7.3, 1.6)	140.4, CH
4''		134.5, C		133.8, C	1.73, m	14.0, CH ₃	1.90, dq (7.3, 1.6)	15.8, CH ₃
5''	7.66, dd (7.4, 2.2)	129.6, CH	7.74, m	128.1, CH	1.71, m	11.6, CH ₃	1.77, t (1.6)	20.2, CH ₃
6''	7.35, m	128.9, CH	7.43, m	130.3, CH				
7''	7.35, m	127.8, CH	7.43, m	128.7, CH				
8''	7.35, m	128.9, CH	7.43, m	130.3, CH				
9''	7.66, dd (7.4, 2.2)	129.6, CH	7.74, m	128.1, CH				
1'''						166.5, C		166.5, C
2'''						127.6, C		126.8, C
3'''					6.73, m	138.0, CH	6.17, qd (7.3, 1.6)	139.2, CH
4'''					1.73, m	14.0, CH ₃	1.85, dq (7.3, 1.6)	15.8, CH ₃
5'''					1.71, m	11.6, CH ₃	1.77, t (1.6)	20.2, CH ₃
1''''					4.57, d (1.7)	101.6, CH	4.59, d (1.8)	101.8, CH
2''''					3.76, m	70.1, CH	3.76, m	70.3, CH
3''''					3.48, dd (9.4, 5.6, 3.2)	70.1, CH	3.47, dd (9.4, 3.2)	70.4, CH
4''''					3.17, td (9.4, 5.6)	71.4, CH	3.18, t (9.4)	71.7, CH
5''''					3.65, m	68.9, CH	3.66, m	69.1, CH
6''''					0.91, d (6.1)	17.5, CH ₃	0.95, d (6.2)	18.0, CH ₃

Table 7
Antitrypanosomatid, antiplasmodial and cytotoxic activities of compounds 1–4, 6–18.

Compound	<i>T. b. rhodesiense</i>	<i>T. cruzi</i>	<i>L. donovani</i>	<i>P. falciparum</i>	Cytotoxicity
	IC ₅₀ [μM]				
1	49.3	88.0	>100	>100	>100
2	80.9	>100	>100	>100	>100
3	>100	>100	>100	>100	>100
4	>100	>100	>100	>100	>100
6	>100	>100	>100	94.0	>100
7	>100	>100	>100	>100	>100
8	>100	>100	66.2	27.2	>100
9	>100	>100	>100	65.7	>100
10	>100	>100	68.9	>100	>100
11	25.7	>100	94.6	6.8	>100
12	23.7	>100	81.8	7.3	>100
13	21.2	>100	>100	6.3	>100
14	17.5	>100	>100	8.7	>100
15	11.6	>100	53.2	2.8	>100
16	13.1	>100	91.1	6.0	>100
17	94.5	>100	>100	26.1	>100
18	18.9	>100	>100	6.3	>100
<i>Schizanthus</i> extract ^a	31.8	65.0	59.6	8.9	>100
Melarsoprol ^b	0.013				
Benznidazole ^b		2.8			
Miltefosine ^b			0.55		
Chloroquine ^b				0.006	
Podophyllotoxin ^b					0.027

Results are the means of two independent assays.

^a IC₅₀ is expressed in μg/mL.^b Positive controls.

Hinds Instruments, Hillsboro, OR, USA) set at 1/4 retardation was used to modulate the handedness of the circular polarized light. Demodulation was performed by a lock-in amplifier (SR830 DSP, Stanford Research System, Sunnyvale, CA, USA). An optical low-pass filter ($<1800\text{ cm}^{-1}$) in front of the photoelastic modulator was used to enhance the signal/noise ratio. Solutions of 2.5–4 mg in 170 μL of DMSO- d_6 were prepared and measured in a transmission cell equipped with CaF₂ windows and a 200 μm spacer. Artifacts were eliminated by subtracting the VCD spectrum of the pure solvent (reference) from the VCD spectrum of the compound. For both the sample and the reference, ca. 24,000 scans at 4 cm^{-1} resolution were averaged. UV spectra were recorded on a PerkinElmer Lambda-25 UV-vis spectrophotometer (Wellesley, MA, USA). IR spectra were measured on a PerkinElmer Spectrum 100 spectrometer. NMR spectra were recorded on a Bruker Avance III HD 600 MHz NMR spectrometer equipped with a QCI 5 mm Cryoprobe and a SampleJet automated sample changer (Bruker BioSpin, Rheinstetten, Germany). Chemical shifts are reported in parts per million (δ) using the residual CD₃OD signals (δ_{H} 3.31; δ_{C} 49.0) or DMSO- d_6 signal (δ_{H} 2.50; δ_{C} 39.5) as internal standards for ¹H and ¹³C NMR, respectively. HRMS spectra were obtained on a Q Exactive Focus Hybrid quadrupole-orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) using electrospray in the positive mode. The spray voltage was set to 3.5 kV; the sheath gas flow rate (N₂) to 50 units; the capillary temperature to 320 °C; the S lens RF level to 50; and the probe heater temperature to 425 °C. UHPLC was performed on an Acquity UPLC I-class System (Waters, Milford, MA, USA). The separation was performed on an Acquity BEH C₁₈ UPLC column (150 × 2.1 mm i.d.; 1.7 μm , Waters), using a gradient (H₂O and MeCN both containing 0.1% formic acid) of 5–30% MeCN in 35 min, followed by a washing step with 98% MeCN for 2 min. After the washing step, the column was equilibrated with 5% MeCN for 5 min before the next injection. The flow rate was set to 0.4 mL/min, the temperature to 40 °C, and the injection volume was 1 μL . Flash chromatography was performed on an Armen Spot preparative chromatographic system (Interchim, Montluçon, France) equipped with a quaternary pump, a UV detector, and a fraction collector. Reverse phase semi-preparative chromatography was performed on an Armen Spot preparative chromatographic system with a Kinetex Axia Core Shell C₁₈ column (250 × 21.2 mm; 5 μm , Phenomenex) or an X-Select CSH C₁₈ column (250 × 19 mm, 5 μm ; Waters). The flow rate was set to 20 and 18 mL/min, respectively, and UV absorbance was at 220 nm. The control of fractions was carried out by an Acquity UPLC System (Waters) equipped with an Acquity PDA detector and connected to a Quattro Micro triple quadrupole mass spectrometer (Waters) with an ESI source operating in positive mode.

4.2. NMR computational details

All calculations have been performed with the Gaussian 16 program (Frisch et al., 2016). Geometry optimization has been achieved using density function theory (DFT) with the B3LYP functional and the 6-31G (d) basis set in the gas-phase. Vibrational analysis was completed at the same level to confirm a minimum. NMR prediction was performed using the mPW1PW91/6-31 + g(d,p) level.

4.3. Plant material

The aerial parts of *Schizanthus tricolor* Grau & Gronbach (Solanaceae) were collected in December 2003 in Cachagua, Chile (GPS coordinates 32°59'S; 71°44'W). Their identification was confirmed by Prof. Fernanda Pérez (Departamento de Botánica, Universidad de Chile). A voucher specimen was deposited at the Facultad de Ciencias Químicas (N° 2000-3).

4.4. Extraction and isolation

The plant material (1.3 kg) was extracted successively with hexane

and MeOH at room temperature. After filtration, the alcoholic solution was evaporated to dryness. The residue (161.2 g) was taken up in 0.1 M HCl and extracted with Et₂O. The aqueous solution was basified with 4% NH₄OH to pH 12 and then extracted with CH₂Cl₂. The organic solvent was dried with anhydrous Na₂SO₄, filtered, and evaporated, yielding 3.7 g of a gummy alkaline residue. The residue was submitted to a fractionation using two flash columns connected in series (PF-C₁₈HQ/120 g, 15 μm C₁₈, Interchim) with a gradient of 5–40% MeCN + 0.1% FA in 2 h and afforded 35 fractions. Fractions 1 and 2 were grouped (91.5 mg) and fractionated with the Kinetex column using a gradient of 0–15% MeOH + 0.1% NH₄OH in 90 min, and yielded **1** (15.1 mg), **2** (6.0 mg), and **3** (2.5 mg). Fraction 3 (23.9 mg) was separated with the Kinetex column using a gradient of 5–20% MeOH + 0.1% NH₄OH in 60 min and afforded **4** (2.3 mg) and **21** (0.3 mg). Fraction 4 (40.8 mg) was separated with the X-Select column using a gradient of 5–25% MeOH + 0.1% NH₄OH in 60 min and gave **5** (0.7 mg), **6** (1.4 mg), **7** (1.0 mg) and **22** (0.3 mg). Fraction 5 (28.4 mg) was separated with the Kinetex column using a gradient of 10–30% MeOH + 0.1% NH₄OH in 60 min and afforded **8** (3.0 mg), **23** (0.2 mg) and **24** (0.3 mg). Fraction 6 (40.3 mg) was separated with the Kinetex column using a gradient of 10–30% ACN in 60 min and afforded **9** (2.6 mg), **25** (0.2 mg) and **26** (0.2 mg). Fraction 7 (35.4 mg) was separated with the Kinetex column using a gradient of 15–35% MeOH + 0.1% NH₄OH in 60 min and gave **10** (1.0 mg) and **17** (0.9 mg). Fraction 8 (30.4 mg) was separated with the Kinetex column using a gradient of 15–40% MeOH + 0.1% NH₄OH in 60 min and gave **19** (0.5 mg). Fraction 10 (20.8 mg) was separated with the X-Select column using a gradient of 15–40% MeOH + 0.1% NH₄OH in 60 min and gave **20** (0.9 mg). Fraction 11 (25.9 mg) was separated with the Kinetex column using a gradient of 15–45% MeOH + 0.1% NH₄OH in 60 min and gave **18** (1.3 mg). Fractions 12 and 13 were grouped (45.8 mg) and fractionated with the Kinetex column using a gradient of 15–40% ACN in 60 min and yielded **11** (3.8 mg). Fraction 15 (16.6 mg) was separated with the Kinetex column using a gradient of 20–45% MeOH + 0.1% NH₄OH in 60 min and afforded **12** (4.0 mg). Fraction 18 (40.6 mg) was separated with the Kinetex column using a gradient of 20–45% MeOH + 0.1% NH₄OH in 60 min and gave **13** (1.6 mg). Fraction 22 (32.0 mg) was separated with the X-Select column using a gradient of 25–50% MeOH + 0.1% NH₄OH in 60 min and gave **14** (1.1 mg). Fraction 25 (28.0 mg) was separated with the X-Select column using a gradient of 30–55% MeOH + 0.1% NH₄OH in 60 min and gave **15** (3.8 mg). Fraction 30 (25.0 mg) was separated with the X-Select column using a gradient of 30–55% MeOH + 0.1% NH₄OH in 60 min and gave **16** (2.5 mg).

4.4.1. Schizanthoside A1 (**1**)

Pale yellow oil; $[\alpha]_D^{22}$ -33.2 (c 0.05, MeOH); UV (MeOH) λ_{max} 222 nm; IR (neat) ν_{max} 3255, 2907, 1592, 1458, 1377, 1342 cm^{-1} ; ¹H and ¹³C NMR, see Table 1; HRESIMS m/z 290.1979 [M + H]⁺ (calcd for C₁₄H₂₇NO₅, 290.1962).

4.4.2. Schizanthoside A2 (**2**)

Pale yellow oil; $[\alpha]_D^{22}$ -56.7 (c 0.05, MeOH); UV (MeOH) λ_{max} 222 nm; IR (neat) ν_{max} 3305, 2923, 1596, 1452, 1345, 1050 cm^{-1} ; ¹H and ¹³C NMR, see Table 1; HRESIMS m/z 290.1979 [M + H]⁺ (calcd for C₁₄H₂₇NO₅, 290.1962).

4.4.3. Schizanthoside A3 (**3**)

Pale yellow oil; $[\alpha]_D^{22}$ -40.3 (c 0.07, MeOH); UV (MeOH) λ_{max} 222 nm; IR (neat) ν_{max} 3293, 2912, 1593, 1455, 1375, 1345 cm^{-1} ; ¹H and ¹³C NMR, see Table 1; HRESIMS m/z 290.1979 [M + H]⁺ (calcd for C₁₄H₂₇NO₅, 290.1962).

4.4.4. Schizanthoside B1 (**4**)

Pale yellow oil; $[\alpha]_D^{22}$ -78.6 (c 0.07, MeOH); UV (MeOH) λ_{max} 220 nm; IR (neat) ν_{max} 3325, 2934, 1711, 1599, 1457, 1376 cm^{-1} ; ¹H and ¹³C

NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.5. Schizanthoside B2 (5)

Pale yellow oil; $[a]_D^{22}$ and IR not measured due to lack of material; UV (MeOH) λ_{max} 220 nm; 1H and ^{13}C NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.6. Schizanthoside B3 (6)

Pale yellow oil; $[a]_D^{22}$ - 71.6 (c 0.05, MeOH); UV (MeOH) λ_{max} 220 nm; IR (neat) ν_{max} 3351, 2929, 1706, 1595, 1457, 1353 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.7. Schizanthoside B4 (7)

Pale yellow oil; $[a]_D^{22}$ - 81.0 (c 0.05, MeOH); UV (MeOH) λ_{max} 220 nm; IR (neat) ν_{max} 3352, 2970, 2927, 1714, 1650, 1599, 1449, 1142, 1082, 1043 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.8. Schizanthoside B5 (8)

Pale yellow oil; $[a]_D^{22}$ - 62.7 (c 0.05, MeOH); UV (MeOH) λ_{max} 220 nm; IR (neat) ν_{max} 3360, 2936, 1713, 1597, 1457, 1352 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.9. Schizanthoside B6 (9)

Pale yellow oil; $[a]_D^{22}$ - 72.2 (c 0.05, MeOH); UV (MeOH) λ_{max} 220 nm; IR (neat) ν_{max} 3344, 2927, 1712, 1597, 1453, 1380 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.10. Schizanthoside B7 (10)

Pale yellow oil; $[a]_D^{22}$ - 91.8 (c 0.05, MeOH); UV (MeOH) λ_{max} 220 nm; IR (neat) ν_{max} 3307, 2935, 1706, 1650, 1597, 1449, 1026 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 2 and 3](#); HRESIMS m/z 372.2385 $[M + H]^+$ (calcd for $C_{19}H_{34}NO_6$, 372.2381).

4.4.11. Schizanthoside C1 (11)

Pale yellow oil; $[a]_D^{22}$ - 65.1 (c 0.07, MeOH); UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3376, 2934, 1713, 1600, 1457, 1354 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 4 and 5](#); HRESIMS m/z 454.2797 $[M + H]^+$ (calcd for $C_{24}H_{40}NO_7$, 454.2800).

4.4.12. Schizanthoside C2 (12)

Pale yellow oil; $[a]_D^{22}$ - 65.4 (c 0.07, MeOH); UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3341, 2934, 1713, 1602, 1457, 1356 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 4 and 5](#); HRESIMS m/z 454.2797 $[M + H]^+$ (calcd for $C_{24}H_{40}NO_7$, 454.2800).

4.4.13. Schizanthoside C3 (13)

Pale yellow oil; $[a]_D^{22}$ - 32.2 (c 0.05, MeOH); UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3351, 2970, 1723, 1602, 1449, 1367 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 4 and 5](#); HRESIMS m/z 454.2797 $[M + H]^+$ (calcd for $C_{24}H_{40}NO_7$, 454.2800).

4.4.14. Schizanthoside C4 (14)

Pale yellow oil; $[a]_D^{22}$ - 46.7 (c 0.05, MeOH); UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3351, 2927, 1713, 1596, 1453, 1037 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 4 and 5](#); HRESIMS m/z 454.2797 $[M + H]^+$ (calcd for $C_{24}H_{40}NO_7$, 454.2800).

4.4.15. Schizanthoside C5 (15)

Pale yellow oil; $[a]_D^{22}$ - 46.5 (c 0.07, MeOH); UV (MeOH) λ_{max} 221 nm;

IR (neat) ν_{max} 3353, 2935, 1719, 1595, 1456, 1377 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 4 and 5](#); HRESIMS m/z 454.2797 $[M + H]^+$ (calcd for $C_{24}H_{40}NO_7$, 454.2800).

4.4.16. Schizanthoside C6 (16)

Pale yellow oil; $[a]_D^{22}$ - 45.7 (c 0.07, MeOH); UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3353, 2970, 1739, 1456, 1368 cm^{-1} ; 1H and ^{13}C NMR, see [Tables 4 and 5](#); HRESIMS m/z 454.2797 $[M + H]^+$ (calcd for $C_{24}H_{40}NO_7$, 454.2800).

4.4.17. Schizanthoside D1 (17)

Pale yellow oil; $[a]_D^{22}$ - 43.2 (c 0.05, MeOH); UV (MeOH) λ_{max} 221, 282 nm; IR (neat) ν_{max} 3327, 2940, 2831, 1709, 1601, 1450, 1023 cm^{-1} ; 1H and ^{13}C NMR, see [Table 6](#); HRESIMS m/z 420.2388 $[M + H]^+$ (calcd for $C_{23}H_{34}NO_6$, 420.2381).

4.4.18. Schizanthoside D2 (18)

Pale yellow oil; $[a]_D^{22}$ - 74.3 (c 0.05, MeOH); UV (MeOH) λ_{max} 220, 282 nm; IR (neat) ν_{max} 3350, 2939, 2830, 1715, 1597, 1450, 1024 cm^{-1} ; 1H and ^{13}C NMR, see [Table 6](#); HRESIMS m/z 420.2388 $[M + H]^+$ (calcd for $C_{23}H_{34}NO_6$, 420.2381).

4.4.19. Schizanthoside E1 (19)

Pale yellow oil; $[a]_D^{22}$ not measured due to lack of material; UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3349, 2930, 1711, 1597, 1454, 1024 cm^{-1} ; 1H and ^{13}C NMR, see [Table 6](#); HRESIMS m/z 600.3386 $[M + H]^+$ (calcd for $C_{30}H_{50}NO_{11}$, 600.3379).

4.4.20. Schizanthoside E2 (20)

Pale yellow oil; $[a]_D^{22}$ not measured due to lack of material; UV (MeOH) λ_{max} 221 nm; IR (neat) ν_{max} 3351, 2937, 1708, 1596, 1452, 1024 cm^{-1} ; 1H and ^{13}C NMR, see [Table 6](#); HRESIMS m/z 600.3386 $[M + H]^+$ (calcd for $C_{30}H_{50}NO_{11}$, 600.3379).

4.5. Acid hydrolysis of 1 and 2

A solution of **1** and **2** (3.0 mg each, individually) in 10% HCl (2 mL) was heated for 3 h. Then, the solution was basified with NaOH (2 M) until pH 12, and then extracted with CH_2Cl_2 (3 \times 4 mL). (–)-Hygroline and (+)-pseudohygroline were confirmed by comparison of their optical rotation with the literature ([Liniger et al., 2013](#)) or by comparison with a reference sample for the L-fucose; $[\alpha]_D^{20}$ -75.5 (c 4, H_2O).

4.6. Antitrypanosomal, antileishmanial, antiplasmodial, and cytotoxicity assays

The in vitro activity against *T. b. rhodesiense*, *T. cruzi*, *L. donovani* and *P. falciparum* as well as cytotoxicity assessment in L6 cells were determined as reported elsewhere ([Bernal et al., 2020](#)). The strains were *T. b. rhodesiense* STIB 900 bloodstream form (trypomastigote), *T. cruzi* Tulahuén C2C4 (LacZ) amastigote form grown in rat L6 skeletal myoblasts, *L. donovani* MHOM/ET/67/L82 amastigote form, and *P. falciparum* NF54 erythrocytic stage. Results are expressed in μM for pure compounds.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank Romina Rocchetti, Sonja Märki and Monical Cal for expert technical assistance in drug testing. This work was supported by the

Swiss National Science Foundation (SNF grant CRSII5_183536). The Institute of Pharmaceutical Sciences of Western Switzerland is thankful to the Swiss National Science Foundation for the support in the acquisition of the NMR 600 MHz (SNF R'Equip grant 316030_164095).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.phytochem.2021.112957>.

References

- Bernal, F.A., Kaiser, M., Wunsch, B., Schmidt, T.J., 2020. Structure–Activity relationships of cinnamate ester analogues as potent antiprotozoal agents. *ChemMedChem* 15, 68–78. <https://doi.org/10.1002/cmdc.201900544>.
- Bhat, C., Tilve, S.G., 2011. Synthesis of (-)-hygrine, (-)-norhygrine, (-)-pseudohygroline and (-)-hygroline via nef reaction. *Tetrahedron Lett.* 52, 6566–6568. <https://doi.org/10.1016/j.tetlet.2011.09.118>.
- Christen, P., Cretton, S., Humam, M., Bieri, S., Munoz, O., Joseph-Nathan, P., 2020. Chemistry and biological activity of alkaloids from the genus *Schizanthus*. *Phytochemistry Rev.* 19, 615–641. <https://doi.org/10.1007/s11101-018-9598-5>.
- Cretton, S., Bartholomeusz, T.A., Mehl, F., Allenbach, Y., Matheussen, A., Cos, P., Maes, L., Christen, P., 2014a. Synthesis and in vitro evaluation of tropane halogenated-derivatives against malaria, sleeping sickness, Chagas disease and leishmaniasis. *Med. Chem.* 10, 753–758. <https://doi.org/10.2174/1573406410666140507095430>.
- Cretton, S., Breant, L., Pourrez, L., Ambuehl, C., Marcourt, L., Ebrahimi, S.N., Hamburger, M., Perozzo, R., Karimou, S., Kaiser, M., Cuendet, M., Christen, P., 2014b. Antitrypanosomal quinoline alkaloids from the roots of *waltheria indica*. *J. Nat. Prod.* 77, 2304–2311. <https://doi.org/10.1021/np5006554>.
- Cretton, S., Glauser, G., Jeannerat, D., Munoz, O., Maes, L., Christen, P., Hostettmann, K., 2010. Isomeric tropane alkaloids from the aerial parts of *Schizanthus tricolor*. *J. Nat. Prod.* 73, 844–847. <https://doi.org/10.1021/np900780w>.
- Cretton, S., Kaiser, M., Karimou, S., Ebrahimi, S.N., Maser, P., Cuendet, M., Christen, P., 2020. Pyridine-4(1H)-one alkaloids from *waltheria indica* as antitrypanosomatid agents. *J. Nat. Prod.* 83, 3363–3371. <https://doi.org/10.1021/acs.jnatprod.0c00671>.
- De la Fuente, G., Reina, M., Muñoz, O., San Martín, A., Girault, J.P., 1988. Tropane alkaloids from *Schizanthus pinnatus*. *Heterocycles* 27, 1887–1897. <https://doi.org/10.3987/COM-88-4562>.
- Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Petersson, G.A., Nakatsuji, H., Li, X., Caricato, M., Marenich, A.V., Bloino, J., Janesko, B.G., Gomperts, R., Mennucci, B., Hratchian, H. P., Ortiz, J.V., Izmaylov, A.F., Sonnenberg, J.L., Williams, Ding F., Lipparini, F., Egidi, F., Goings, J., Peng, B., Petrone, A., Henderson, T., Ranasinghe, D., Zakrzewski, V.G., Gao, J., Rega, N., Zheng, G., Liang, W., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Throssell, K., Montgomery Jr., J.A., Peralta, J.E., Ogliaro, F., Bearpark, M.J., Heyd, J.J., Brothers, E.N., Kudin, K.N., Staroverov, V.N., Keith, T.A., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A.P., Burant, J.C., Iyengar, S. S., Tomasi, J., Cossi, M., Millam, J.M., Klene, M., Adamo, C., Cammi, R., Ochterski, J. W., Martin, R.L., Morokuma, K., Farkas, O., Foresman, J.B., Fox, D.J., 2016. *Gaussian 16*. Rev. C.01, Wallingford, CT.
- Islam, M.T., Mubarak, M.S., 2020. Pyrrolidine alkaloids and their promises in pharmacotherapy. *Adv. Tradit. Med.* 20, 13–22. <https://doi.org/10.1007/s13596-019-00419-4>.
- Liniger, M., Estermann, K., Altmann, K.-H., 2013. Total synthesis of hygroline and pseudohygroline. *J. Org. Chem.* 78, 11066–11070. <https://doi.org/10.1021/jo4017343>.
- Muñoz, O., Schneider, C., Breitmaier, E., 1994. A new pyrrolidine alkaloid from *Schizanthus integrifolius*. *Liebigs Ann. Chem.* 521–522. <https://doi.org/10.1002/jlac.15619940513>.
- Pérez, F., Arroyo, M.T.K., Medel, R., Hershkovitz, M.A., 2006. Ancestral reconstruction of flower morphology and pollination systems in *Schizanthus* (Solanaceae). *Am. J. Bot.* 93, 1029–1038. <https://doi.org/10.3732/ajb.93.7.1029>.
- Smith, S.G., Goodman, J.M., 2010. Assigning stereochemistry to single diastereoisomers by GIAO NMR calculation: the DP4 probability. *J. Am. Chem. Soc.* 132, 12946–12959. <https://doi.org/10.1021/ja105035r>.
- Taniguchi, T., Monde, K., 2007a. Chiroptical analysis of glycoconjugates by vibrational circular dichroism (VCD). *Trends Glycosci. Glycotecnol.* 19, 147–164. <https://doi.org/10.4052/tigg.19.147>.
- Taniguchi, T., Monde, K., 2007b. Spectrum-structure relationship in carbohydrate vibrational circular dichroism and its application to glycoconjugates. *Chem. Asian J.* 2, 1258–1266. <https://doi.org/10.1002/asia.200700180>.